药物相关性颌骨坏死的机制及治疗研究进展

doi:10.12337/zgkqjxjyzz.2025.05.002

中国口腔医学继续教育杂志 ›› 2025, Vol. 28 ›› Issue (5): 307-311.DOI: 10.12337/zgkqjxjyzz.2025.05.002

药物相关性颌骨坏死的机制及治疗研究进展

何金媛, 孙国文^*

南京大学医学院附属口腔医院口腔颌面头颈外科,南京市口腔医院,南京大学口腔医学研究所

出版日期:2025-09-30 发布日期:2025-09-30
通讯作者: ^* 孙国文,联系方式：025-83620326,电子邮箱：238957@sina.com,通讯地址：江苏省南京市玄武区中央路30号,210008

Research Progress on the Mechanism and Treatment of Medication-related Osteonecrosis of the Jaw

Jinyuan He, Guowen Sun^*

Department of Oral and Maxillofacial-Head and Neck Surgery, Nanjing Stomatological Hospital, Medical School of Nanjing University, Institute of Stomatology, Nanjing University, Nanjing, Jiangsu Province, P.R. China

Online:2025-09-30 Published:2025-09-30
Contact: Guowen Sun. Tel: 025-83620326. Email: 238957@sina.com. Address: No.30 Central Road, Xuanwu District, Nanjing 210008, Jiangsu Province, P.R. China.

摘要/Abstract

摘要： 药物相关性颌骨坏死（medication-related osteonecrosis of the jaw,MRONJ）是一种主要与抗骨吸收和抗血管生成等药物使用有关的发生于颌骨的严重并发症。本文描述了MRONJ的发病机制、危险因素、诊断方法及防治策略的最新研究进展。MRONJ的发病机制涉及药物对骨代谢的影响、血管生成抑制、局部感染和免疫反应等多个方面。早期诊断和预防对于改善预后至关重要。其治疗以手术治疗为主,新兴治疗方法如己酮可可碱联合α-生育酚的药物协同疗法和新技术辅助手术,但未来仍需进一步开展大规模临床研究以优化防治策略。

Abstract: Medication-related osteonecrosis of the jaw（MRONJ）is a serious complication that occurs in the jaw and is mainly related to the use of drugs such as antiresorptive and antiangiogenic drugs. This article reviews the latest research progress on the pathogenesis, risk factors, diagnostic methods, and prevention strategies of MRONJ. The pathogenesis of MRONJ involves the effects of drugs on bone metabolism, angiogenesis inhibition, local infection and immune response. Early diagnosis and prevention are essential to improve outcomes. At present, the treatment of MRONJ is mainly surgical, and there are also some emerging treatments, such as the synergistic therapy of pentoxifylline+α-tocopherol and the application of new technologies to assist in surgical treatment. Large-scale clinical studies are needed in the future to optimize the prevention and treatment strategies of MRONJ.

Key words: medication-related osteonecrosis of the jaw, antiresorptive drugs, antiangiogenic drugs, pathogenesis, treatment

何金媛, 孙国文. 药物相关性颌骨坏死的机制及治疗研究进展[J]. 中国口腔医学继续教育杂志, 2025, 28(5): 307-311.

Jinyuan He, Guowen Sun. Research Progress on the Mechanism and Treatment of Medication-related Osteonecrosis of the Jaw[J]. Chinese Journal of Stomatological Continuing Education, 2025, 28(5): 307-311.

参考文献

[1] Marx RE.Pamidronate(Aredia) and zoledronate(Zometa) induced avascular necrosis of the jaws: a growing epidemic[J]. J Oral Maxillofac Surg, 2003, 61(9):1115-1117.
[2] Ruggiero SL, Dodson TB, Fantasia J, et al.American Association of Oral and Maxillofacial Surgeons position paper on medication-related osteonecrosis of the jaw--2014 update[J]. J Oral Maxillofac Surg, 2014, 72(10):1938-1956.
[3] 侯伟, 董肖婷, 吴婷婷, 等. 药物相关性颌骨坏死的病因特点和临床治疗初探[J].中华口腔医学杂志, 2021, 56(7):659-664 .
[4] Ruggiero SL, Dodson TB, Aghaloo T, et al.American Association of Oral and Maxillofacial Surgeons Position Paper on Medication-Related Osteonecrosis of the Jaw-2022 Update[J]. J Oral Maxillofac Surg, 2022, 80(5):920-943.
[5] Bracchi P, Zecca E, Brunelli C, et al.A real-world study on the prevalence and risk factors of medication related osteonecrosis of the jaw in cancer patients with bone metastases treated with Denosumab[J]. Cancer Med, 2023, 12(17):18317-18326.
[6] 何悦, 陈珩, 安金刚, 等. 药物相关性颌骨坏死临床诊疗专家共识[J]. 中国口腔颌面外科杂志, 2023, 21(4):313-325.
[7] Bassan Marinho Maciel G, Marinho Maciel R, Linhares Ferrazzo K, et al. Etiopathogenesis of medication-related osteonecrosis of the jaws: a review[J]. J Mol Med (Berl), 2024, 102(3):353-364.
[8] Rosella D, Papi P, Giardino R, et al.Medication-related osteonecrosis of the jaw: Clinical and practical guidelines[J]. J Int Soc Prev Community Dent, 2016, 6(2):97-104.
[9] Anastasilakis AD, Pepe J, Napoli N, et al.Osteonecrosis of the Jaw and Antiresorptive Agents in Benign and Malignant Diseases: A Critical Review Organized by the ECTS[J]. J Clin Endocrinol Metab, 2022, 107(5):1441-1460.
[10] 姜志深, 曹钰彬, 曹志炜, 等. 地舒单抗用药人群拔牙围手术期管理的研究进展[J]. 中华口腔医学杂志, 2024, 59(8):840-845.
[11] 苏传超, 林梓桐, 王靖斐, 等. 药物相关性颌骨坏死对比化脓性颌骨骨髓炎影像学及临床特点的研究[J]. 口腔医学研究, 2024, 40(12):1065-1070.
[12] 孙国文, 田美. 药物相关性颌骨坏死不同阶段治疗方法述评[J]. 口腔颌面外科杂志, 2022, 32(3):135-143.
[13] 田美, 王丹妮, 罗舒艳, 等. 上颌骨药物相关性颌骨坏死的手术治疗效果初探[J].中华口腔医学杂志, 2021, 56(5):447-451.
[14] Tomo S, da Cruz TM, Figueira JA, et al. Fluores-cenceguided surgical management of medication-related osteonecrosis of the jaws[J]. Photodiagnosis Photodyn Ther, 2020, 32:102003.
[15] 高娜, 田美, 孙亚威, 等. 骨管技术在Ⅱ期下颌骨药物相关性颌骨坏死手术中的应用初探[J]. 华西口腔医学杂志, 2024, 42(5):629-635.
[16] Yüce MO, Adalı E, Işık G.The effect of concentrated growth factor (CGF) in the surgical treatment of medication-related osteonecrosis of the jaw (MRONJ) in osteoporosis patients: a randomized controlled study[J]. Clin Oral Investig, 2021, 25(7):4529-4541.
[17] Freiberger JJ, Padilla-Burgos R, Chhoeu AH, et al.Hyperbaric oxygen treatment and bisphosphonate-induced osteonecrosis of the jaw: A case series[J]. J Oral Maxillofac Surg, 2007, 65(7):1321-1327.
[18] 陈思静, 李玉洁, 彭玲. 高压氧联合唑来膦酸治疗老年骨质疏松患者疗效及对骨密度、血清骨代谢生化标志物的影响[J]. 中华航海医学与高气压医学杂志, 2024, 31(6):780-784.
[19] Słowik Ł, Totoń E, Nowak A, et al.Pharmacological Treatment of Medication-Related Osteonecrosis of the Jaw (MRONJ) with Pentoxifylline and Tocopherol[J]. J Clin Med, 2025, 14(3):974.
[20] Bennardo F, Barone S, Antonelli A, et al.Autologous platelet concentrates as adjuvant in the surgical management of medication-related osteonecrosis of the jaw[J]. Periodontol 2000, 2025, 97(1):287-307.
[21] Ruan HJ, Chen H, Hou JS, et al.Chinese expert consensus on the diagnosis and clinical management of medication-related osteonecrosis of the jaw[J]. J Bone Oncol, 2024, 49:100650.
[22] Yarom N, Shapiro CL, Peterson DE, et al.Medication-Related Osteonecrosis of the Jaw: MASCC/ISOO/ASCO Clinical Practice Guideline[J]. J Clin Oncol, 2019, 37(25):2270-2290.

药物相关性颌骨坏死的机制及治疗研究进展

Research Progress on the Mechanism and Treatment of Medication-related Osteonecrosis of the Jaw

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	丁一辉, 王丹丹, 李晨璐, 王继弘, 田磊, 宗春琳. 特立帕肽在药物相关性颌骨坏死中治疗作用的研究进展[J]. 中国口腔医学继续教育杂志, 2025, 28(5): 297-306.
[2]	徐冰玥, 鲁涵, 刘柯蓥, 何巍. 药物相关性颌骨坏死中微生态失衡的研究进展[J]. 中国口腔医学继续教育杂志, 2025, 28(5): 312-321.
[3]	张逸云, 康非吾, 张雪明. 药物相关性颌骨坏死非手术治疗的研究进展[J]. 中国口腔医学继续教育杂志, 2025, 28(5): 322-330.
[4]	江晨曦, 孙国文. 药物相关性颌骨坏死临床诊疗的研究进展[J]. 中国口腔医学继续教育杂志, 2025, 28(5): 331-336.
[5]	王睿, 孙国文. 3期药物相关性颌骨坏死的手术治疗的回顾性研究[J]. 中国口腔医学继续教育杂志, 2025, 28(5): 345-352.
[6]	刘畅, 赵晓一. 光活化牙齿漂白治疗效果及对牙体硬组织的影响[J]. 中国口腔医学继续教育杂志, 2025, 28(5): 353-359.
[7]	何金媛, 孙国文. 斜面导板改善下颌骨药物相关性颌骨坏死的咬合关系1例[J]. 中国口腔医学继续教育杂志, 2025, 28(5): 360-366.
[8]	李娜, 常远, 高宁, 付坤, 蔡菁华, 高振杰, 乔翔鹤, 杨雷雷, 何巍. 药物相关性颌骨坏死的“互联网+”案例教学法的临床应用[J]. 中国口腔医学继续教育杂志, 2025, 28(5): 367-374.
[9]	释栋, 于晨浩, 司燕, 宋忠臣, 欧阳翔英, 刘怡, 胡文杰, 潘亚萍. 中国牙周健康管理现状与未来策略[J]. 中国口腔医学继续教育杂志, 2025, 28(4): 189-193.
[10]	景雪琴, 侯世豪, 张玖久, 张曦予, 吴瑞鑫, 田蓓敏, 陈发明, 许杰. 一步一步学习引导性组织再生术[J]. 中国口腔医学继续教育杂志, 2025, 28(4): 207-212.
[11]	李哲, 李琛, 潘亚萍. 人工智能在牙周病领域中的应用：现状、挑战与未来展望[J]. 中国口腔医学继续教育杂志, 2025, 28(4): 213-219.
[12]	戚刚刚, 王艺翔, 刘倩, 陈小燕, 李晓军. 牙周-正畸联合治疗广泛型III期C级牙周炎1例[J]. 中国口腔医学继续教育杂志, 2025, 28(4): 220-236.
[13]	陈方慧, 彭乔, 赵华翔, 孟兆理, 张细萱, 刘子菲, 朱春晖. 牙周-正畸-种植多学科联合治疗Ⅳ期C级牙周炎1例[J]. 中国口腔医学继续教育杂志, 2025, 28(4): 246-258.
[14]	侯海娟, 赵美林, 黄诗淇, 危晶晶, 徐骏疾. 下颌前磨牙邻面牙周再生观察3年1例[J]. 中国口腔医学继续教育杂志, 2025, 28(4): 259-268.
[15]	程佳佳, 陈广生, 王茹楠, 何欣, 蒋宇杰, 葛颂, 高丽. 牙周-正畸-修复联合治疗安氏Ⅰ类错𬌗畸形伴下前牙牙龈退缩1例[J]. 中国口腔医学继续教育杂志, 2025, 28(4): 269-283.